US Cancer Vaccine Market Outlook 2022

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or Email: pdb@bioportfolio.co.uk
US Cancer Vaccine Market Outlook 2022

Cancer is one of the major health issues faced by the countries across the globe. The researchers are engaged in developing various drugs for the prevention and treatment of the disease. Cancer vaccine is one such example. Since their inception, cancer vaccines were considered as high potential method for preventing and treating cancer. Till date, the vaccines have not been able to achieve the expected sales due to high cost and negative results in clinical trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen; and increasing awareness of people regarding these vaccines, the market is expected to grow.

The US is largest market for cancer vaccines. The growth of the US cancer vaccine market is driven by increasing cancer incidence in the country, rising awareness, and strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides detailed analysis of the market. This report covers the present scenario and the growth prospects of US cancer vaccine market for the period 2015-2022. It also covers the drivers, restraints hampering the growth of the market, and future opportunities. Moreover, the report provides the global sales of various cancer vaccines from 2013-2015.

On the basis of type of cancer for which the vaccine is targeted, the market has been segmented into three types, namely, liver cancer, HPV related cancer, and others. Currently, HPV related cancer vaccines occupy the largest share in the US market.

On the basis of type of vaccine, the market has been further sub-divided into prophylactic vaccines and therapeutic vaccines. The prophylactic vaccines accounts for the largest share in 2016. The large share of this market is attributed to various vaccination programs organized by the US government for prevention against HPV and hepatitis. The therapeutic vaccines are expected to witness high growth in coming years due to strong pipeline. Amongst the various research studies, a vaccine for lung cancer can be expected to come up soon with promising candidates, such as TV4010 and GV1001, having entered phase 3 trials.

The report also provides market share analysis by key players. Merck and GSK are expected to continue to be undisputed market leaders in the cancer vaccine market. Furthermore, the report also covers the FDA's vaccine approval procedure, and its guidance to the industry for developing therapeutic cancer vaccines. Additionally, the report also enlists the pipeline of cancer vaccines which are in various clinical trial phases. The patent analysis of products in US has also been added in the report on the basis of year of grant, type of patent, and assignee of the patent.

The last section of the report discusses about the key players in the US cancer vaccine market. A brief business overview and financial information about each of these players has been provided in the report. Moreover, this report will help the reader to gain crucial insight into the key players’ performances and strategies for growth. Conclusively, the research will prove to be a useful resource for all debut makers in US cancer vaccine industry and potential investors.

Additional Details

Publisher : RNCOS
Reference :
Number of Pages : 135
Report Format : PDF
Publisher Information :

https://www.biop...
RNCOS is a Business Consulting Service firm providing multiple services to companies wishing to engage in any business expansion. We uniquely position our self as a "one-stop-shop" offering a broad spectrum of Management Consulting and Business facilitation services including but not limited to Financial & Business Assessment, Market Entry / Expansion Strategies, Market and Industry Research, Identification & Selection of Business Partners, Feasibility and Facility Location Studies etc.

Since our inception in 2002, we have gained industry experience and expertise in offering research solutions to distinguished clientele across multi geographies and industry verticals. We help our clients in achieving sustainable performance and better growth prospects by weeding out their obsolete business process with well laid strategies by working in close co-ordination with them.

Be it market entry, product testing, competition assessment, customer satisfaction study, pricing analysis or any other requirement, RNCOS team acts proactively to fit in the best possible solution for our valued clients. We believe in multi-level client interaction and complete transparency from the project commencement till effective implementation, thus ensuring total customer satisfaction.
Table Of Contents for US Cancer Vaccine Market Outlook 2022 [Published by RNCOS]

• 1. Analyst View2. Research Methodology3. Cancer Statistics by Demographics3.1 Prevalence, Incidences and Mortality3.2 Leading States by Incidences3.3 Leading Cancers by Incidences3.3.1 Male Cancer Incidences3.3.2 Female Cancer Incidences3.3.3 Children Cancer Incidences4. Market Dynamics4.1 Drivers4.1.1 Rising Cancer Incidences4.1.2 Ability to Reduce Healthcare Expenditure4.1.3 Rising Awareness4.1.4 Patient Assistance Programs4.1.5 Government Initiatives4.1.6 Strong Pipeline4.1.7 Technological Advancements4.2 Restraints4.2.1 High Cost of Cancer Vaccines4.2.2 Side Effects of Cancer Vaccines4.2.3 Vaccine Supply Shortages4.2.4 Insurance Issues Related to Cancer Vaccination4.3 Opportunities4.3.1 Therapeutic Cancer Vaccines4.3.2 Adjuvant Cancer Vaccines5. Cancer Vaccine Market Outlook5.1 Key Product Analysis5.1.1 Provenge5.1.1.1 Market Analysis5.1.2 T-Vec/Imlygic5.1.2.1 Market Analysis5.1.3 HPV Vaccine5.1.3.1 Gardasil5.1.3.1.1 Market Analysis5.1.3.2 Cervarix5.1.3.2.1 Market Analysis5.1.4 HBV Vaccines5.1.4.1 Engerix-B5.1.4.1.1 Market Analysis5.1.4.2 Recombivax HB5.1.4.2.1 Market Analysis5.1.4.3 Pediarix/Infanrix5.1.4.3.1 Market Analysis6. Cancer Vaccines Market by Cancer Type7. Cancer Vaccine Market by Application8. Potential Cancer Vaccine Candidates: An Opportunity Assessment8.1 Prophylactic Vaccine8.2 Therapeutic Vaccine8.2.1 Prostate Cancer8.2.2 Breast Cancer8.2.3 Lung Cancer8.2.4 Colorectal Cancer9. US Patent Analysis9.1 Patents by Year9.2 Patents by Category9.2.1 Utility Patents9.2.2 Design Patents9.2.3 Plant Patents9.3 Patents by Company9.4 Patents by Assignee Type9.4.1 By Assignee Name9.4.2 By Assignee State10. Regulatory Environment10.1 Vaccine Approval Process10.2 FDA Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines10.2.1 Considerations for both Early and Late Phase Clinical Trials10.2.1.1 Patient Population10.2.1.2 Monitoring the Immune Response10.2.1.3 Biomarkers as Evidence of Efficacy10.2.1.4 Adjuvants Used to Stimulate Immune Response10.2.1.5 Multi-antigen Vaccines10.2.1.6 Disease Progression/Recurrence Immediately or Shortly after the Initial Administration of Cancer Vaccines10.2.1.7 Concomitant and Subsequent Therapies10.2.2 Considerations for Early Phase Clinical Trials10.2.2.1 Starting Dose and Dosing Schedule10.2.2.2 Booster and Maintenance Therapy10.2.2.3 Dose Escalation10.2.2.4 Single-arm versus Randomized Phase-2 Trials in Early Development10.2.3 Considerations for Late Phase Clinical Trials10.2.3.1 Safety Profile from Early Phase Clinical Trials10.2.3.2 Endpoints10.2.3.3 Statistical Issues10.2.3.4 Control Issues10.2.3.5 Delayed Vaccine Effect10.2.3.6 Autologous Vaccine Trials10.2.3.7 Accelerated Approval Regulations11. Competitive Landscape12. Company Profiles12.1 Merck & Co.12.2 GlaxoSmithKline plc12.3 Dendreon (A Subsidiary of Valeant Pharmaceuticals)12.4 Amgen Inc.List of Figures:Figure 3-1: Cancer Incidences (Million), 2015-2022Figure 3-2: Cancer Mortality (Million), 2015-2022Figure 3-3: Incidences by Type of Cancer (%), 2016Figure 3-4: States with Highest Cancer Incidences, 2015Figure 5-1: Share of US in Global Cancer Vaccine Market (%), 2016Figure 5-2: US - Cancer Vaccine Market by Product Type (%), 2016Figure 5-3: Global - Provenge Market (Million US$), 2013-2015Figure 5-4: Share of US in Global Imlygic Sales (%), 2015Figure 5-5: Global - Gardasil Market (Million US$), 2013-2015Figure 5-6: US - Gardasil Market (Million US$), 2013-2015Figure 5-7: Share of US in Global Gardasil Sales (%), 2015Figure 5-8: Global - Cervarix Market (Million US$), 2013-2015Figure 5-9: US - Cervarix Market (Million US$), 2013-2015Figure 5-10: Share of US in Global Cervarix Sales (%), 2015Figure 5-11: Global - Engerix-B Market (Million US$), 2013-2015Figure 5-12: US - Engerix-B Market (Million US$), 2013-2015Figure 5-13: Share of US in Global Engerix-B Sales (%), 2015Figure 5-14: Global - Recombivax HB Market (Million US$), 2013-2015Figure 5-15: US - Recombivax HB Market (Million US$), 2013-2015Figure 5-16: Share of US in Global Recombivax HB Sales (%), 2015Figure 5-17: Global - Pediarix/Infanrix Market (Million US$), 2013-2015Figure 5-18: US - Pediarix/Infanrix Market (Million US$), 2013-2015Figure 5-19: Share of US in Global Pediarix/Infanrix Sales (%), 2015Figure 6-1: US - Cancer Vaccine Market by Cancer Type (%), 2016Figure 6-2: US - Cancer Vaccine Market for Liver Cancer (Million US$), 2015-2022Figure 6-3: US - Cancer Vaccine Market for HPV Related Cancer (Million US$), 2015-2022Figure 6-4: US - Cancer Vaccine Market for Other Cancers (Million US$), 2015-2022Figure 7-1: US - Cancer Vaccine Market by Application (%), 2016Figure 7-2: US - Cancer Vaccine Market for Therapeutic Vaccines (Million US$), 2015-2022Figure 7-3: US - Cancer Vaccine Market for Prophylactic Vaccines (Million US$), 2015-2022Figure 8-1: Prophylactic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016Figure 8-2: Prophylactic Cancer Vaccines in Clinical Trials by Phases (%), 2016Figure 8-3: Therapeutic Cancer Vaccines in Clinical Trials by Cancer Site (%), 2016Figure 8-4: Therapeutic Cancer Vaccines in Clinical Trials by Phases (%), 2016Figure 8-5: Cancer Vaccines in Clinical Trials by Application (%), 2016Figure 11-1: US - Share of Major Players in Cancer Vaccine Market (%), 2015Figure 12-
1: Merck & Co. - Breakup of Revenue by Segment (%), 2015

Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Segment (%), 2015

Figure 12-3: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Segment (%), 2015

List of Tables:
- Table 3-1: Top 10 Cancer Incidences in Males (2015)
- Table 3-2: Top 10 Cancer Incidences in Females (2015)
- Table 3-3: Top 10 Cancer Incidences in Children (Ages 0-14), (2015)
- Table 4-1: US - Cancer Incidences (Million), 2015 & 2020
- Table 5-1: Global - Cancer Vaccine Market (Million US$), 2015-2022
- Table 5-2: US - Cancer Vaccine Market (Million US$), 2015-2022
- Table 8-1: Cancers with High Linkage to Virus and Bacteria
- Table 8-2: Prophylactic Cancer Vaccines in Clinical Trials
- Table 8-3: Therapeutic Cancer Vaccines in Clinical Trials
- Table 8-4: Prostate Cancer Therapeutic Vaccines in Clinical Trials
- Table 8-5: Breast Cancer Therapeutic Vaccines in Clinical Trials
- Table 8-6: Lung Cancer Therapeutic Vaccines in Clinical Trials
- Table 8-7: Colorectal Cancer Therapeutic Vaccines in Clinical Trials
- Table 12-1: Merck & Co. - Key Financials (Million US$), 2013-2015
- Table 12-2: Merck - Product Portfolio
- Table 12-3: Merck - Cancer Vaccines in Pipeline
- Table 12-4: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
- Table 12-5: GlaxoSmithKline - Product Portfolio
- Table 12-6: GlaxoSmithKline - Cancer Vaccines in Pipeline
- Table 12-7: Valeant Pharmaceuticals International, Inc. - Key Financials (Million US$), 2013-2015
- Table 12-8: Dendreon - Product Portfolio
- Table 12-9: Amgen Inc. - Key Financials (Million US$), 2013-2015
- Table 12-10: Amgen Inc. - Product Portfolio
How to Buy...

US Cancer Vaccine Market Outlook 2022 [Published by RNCOS]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/24731

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: _____________________________________________________________
Job Title: ______________________________________________________________
Your Email: _____________________________________________________________
Your Contact Phone: _____________________________________________________
Company Name: _________________________________________________________
Address: _______________________________________________________________
Post/Zip Code: ___________________________________________________________
Country: _______________________________________________________________
P.O. Number: ___________________________________________________________
Any Other Instructions: _________________________________________________

Pricing Options: (please tick one)
○ $1200 | Single User Price
○ $2000 | Multi User Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ___________________________________________________

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.